Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Investigating iLux Efficacy in Contact Lens Wearers With Evaporative Dry Eye Disease (SHEEPDOG)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04159935
Recruitment Status : Recruiting
First Posted : November 12, 2019
Last Update Posted : November 19, 2019
Sponsor:
Collaborator:
Alcon Research
Information provided by (Responsible Party):
University of Waterloo

Brief Summary:
The purpose of this clinical trial is to investigate the efficacy of a single iLux® treatment in symptomatic CL wearers who have DED (according to the TFOS DEWS II diagnostic criteria), of the evaporative dry eye disease subtype (EDE).

Condition or disease Intervention/treatment Phase
Dry Eye Device: iLux® system Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 52 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Investigating iLux Efficacy in Contact Lens Wearers With Evaporative Dry Eye Disease
Actual Study Start Date : November 15, 2019
Estimated Primary Completion Date : June 30, 2020
Estimated Study Completion Date : June 30, 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: iLux® treatment
The treatment group will receive iLux® treatment at Visit 1 and will be reviewed 1- and 3-months after iLux® treatment.
Device: iLux® system
Commercially available medical device intended for use by qualified eye care professionals to apply localized heat and pressure therapy to a patient's eyelids.

Experimental: Delayed iLux® treatment
Delayed iLux® treatment provided after 1 month (i.e. 1 month of no treatment, administer treatment after 1 month). Review 1- and 3-months after iLux® treatment.
Device: iLux® system
Commercially available medical device intended for use by qualified eye care professionals to apply localized heat and pressure therapy to a patient's eyelids.




Primary Outcome Measures :
  1. Mean Change in Dry Eye (SPEED) Questionnaire From Baseline at 1 Month [ Time Frame: 1 month ]
    The mean change in dry eye symptoms from Baseline based on the SPEED questionnaire score was evaluated 1 month after iLux treatment. The SPEED questionnaire evaluates dry eye symptoms based on symptom frequency and severity. A lower SPEED score represents less frequent and/or less severe symptoms.


Secondary Outcome Measures :
  1. Meibomian Gland Score at Baseline [ Time Frame: Baseline ]
    To determine the meibomian gland score, secretion characteristics of 15 meibomian glands along the lower eyelid were evaluated including five glands each in the temporal, central and nasal regions of the lower eyelid. For each gland, secretion characteristics were graded as 3 (clear liquid), 2 (cloudy liquid), 1 (inspissated/ toothpaste consistency) and 0 (no secretion). The total meibomian gland score is the sum of the grades for all 15 glands with a range between 0 and 45. A higher score reflects less meibomian gland dysfunction.

  2. Meibomian Gland Score at 1 Month [ Time Frame: 1 Month ]
    To determine the meibomian gland score, secretion characteristics of 15 meibomian glands along the lower eyelid were evaluated including five glands each in the temporal, central and nasal regions of the lower eyelid. For each gland, secretion characteristics were graded as 3 (clear liquid), 2 (cloudy liquid), 1 (inspissated/ toothpaste consistency) and 0 (no secretion). The total meibomian gland score is the sum of the grades for all 15 glands with a range between 0 and 45. A higher score reflects less meibomian gland dysfunction.

  3. Meibomian Gland Score at 3 Months [ Time Frame: 3 Months ]
    To determine the meibomian gland score, secretion characteristics of 15 meibomian glands along the lower eyelid were evaluated including five glands each in the temporal, central and nasal regions of the lower eyelid. For each gland, secretion characteristics were graded as 3 (clear liquid), 2 (cloudy liquid), 1 (inspissated/ toothpaste consistency) and 0 (no secretion). The total meibomian gland score is the sum of the grades for all 15 glands with a range between 0 and 45. A higher score reflects less meibomian gland dysfunction.

  4. Comfortable Contact Lens Wear Time at Baseline [ Time Frame: Baseline ]
    Participants reported how long they wore their contact lenses on average per day (total wear time) and how long the contact lenses on average were comfortable (comfortable wear time).

  5. Comfortable Contact Lens Wear Time at 1 Month [ Time Frame: 1 Month ]
    Participants reported how long they wore their contact lenses on average per day (total wear time) and how long the contact lenses on average were comfortable (comfortable wear time).

  6. Comfortable Contact Lens Wear Time at 3 Months [ Time Frame: 3 Months ]
    Participants reported how long they wore their contact lenses on average per day (total wear time) and how long the contact lenses on average were comfortable (comfortable wear time).

  7. Pre-lens Tear Break-up Time at Baseline [ Time Frame: Baseline ]
    The pre-lens tear film is the layer of tears located on top of the contact lens (i.e., between the eye lid and the contact lens). The time required for a dry spot to appear on the contact lens surface after blinking is referred to as the pre-lens tear break-up time. Three measurements are taken and averaged together. A higher number represents a longer pre-lens tear break-up time.

  8. Pre-lens Tear Break-up Time at 1 Month [ Time Frame: 1 Month ]
    The pre-lens tear film is the layer of tears located on top of the contact lens (i.e., between the eye lid and the contact lens). The time required for a dry spot to appear on the contact lens surface after blinking is referred to as the pre-lens tear break-up time. Three measurements are taken and averaged together. A higher number represents a longer pre-lens tear break-up time.

  9. Pre-lens Tear Break-up Time at 3 Months [ Time Frame: 3 Months ]
    The pre-lens tear film is the layer of tears located on top of the contact lens (i.e., between the eye lid and the contact lens). The time required for a dry spot to appear on the contact lens surface after blinking is referred to as the pre-lens tear break-up time. Three measurements are taken and averaged together. A higher number represents a longer pre-lens tear break-up time.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Is at least 18 years of age and has full legal capacity to volunteer;
  2. Has read and signed an information consent letter;
  3. Is willing and able to follow instructions and maintain the appointment schedule;
  4. Has been using the same CL type (brand, material and dimensions) for > 3 months;
  5. Wears commercially available soft CLs on average >2 hours per day, 4-7 days per week;
  6. Is willing to try to wear their habitual CLs on average ≥ 6 hours per day, 4-7 days per week and maintain this for the duration of their involvement in the study;
  7. Demonstrates an acceptable lens fit of their habitual contact lenses;
  8. Does not have contact lens discomfort due to contact lens fit, lens material or known solution compatibility issues, in the opinion of the investigator;
  9. Has at least one month supply of their habitual contact lens products at the time of the screening visit;
  10. Has a CLDEQ-8 score ≥ 12;
  11. Has dry eye symptoms without CL wear (OSDI ≥ 13) and has at least one of the two following signs:

    1. Non-invasive tear break-up time (NITBUT) of < 10 seconds in at least one eye;
    2. Fluorescein staining: > 5 spots of corneal staining OR > 9 conjunctival spots OR lid wiper staining (≥ 2mm length, ≥ 25% width) in at least one eye;
  12. Has a lipid layer thickness of ≤ 100 nm in both eyes;
  13. A meibomian gland secretion score (MGS) of ≤ 15 for 15 glands of the lower lid in both eyes.

Exclusion Criteria:

  1. Is participating in any concurrent clinical or research study;
  2. Has used any prescription systemic medications or topical treatments for MGD or dry eye for the past 30 days prior to the screening visit and not willing to stop using these for the study duration (excluding over-the-counter artificial tears, dietary supplements and ocular lubricants but includes warm compresses, eyelid massage, eyelid hygiene, manual meibomian gland expression, punctal plug insertion or punctal occlusion, intense pulsed light treatment of the face or eyelids);
  3. Has previously received treatment with an eyelid thermal pulsation device;
  4. Has a history of any of the following ocular (eye or eyelid) conditions or procedures in either eye within the past 90 days prior to the screening visit:

    1. Ocular trauma
    2. Chemical burns
    3. Ocular Herpes simplex or Herpes zoster infection
    4. Limbal stem cell deficiency
    5. Recurrent ocular inflammation (e.g. uveitis, iritis, scleritis, episcleritis, keratitis)
  5. Has undergone ocular surgery (e.g. intraocular, oculoplastic, corneal or refractive surgery procedure) within the past 12 months prior to the screening visit;
  6. Has permanent make-up or tattoos on their eyelids;
  7. Has any other known active* ocular disease and/or infection in either eye including: cicatricial lid margin disease or severe (≥ grade 3) blepharitis; moderate to severe (grade 2-4) allergic, vernal or giant papillary conjunctivitis; a hordeolum or stye; ocular surface abnormality that may compromise corneal integrity (e.g. Grade 3 corneal fluorescein staining, recurrent corneal erosion, corneal epithelial defect, map dot fingerprint dystrophy, previously treated chemical burn);
  8. Has an eyelid abnormality that affects normal lid function (e.g. entropion, ectropion, oedema, blepharospasm, lagophthalmos, severe trichiasis, severe ptosis);
  9. Has a systemic condition that in the opinion of the investigator may affect a study outcome variable;
  10. Has any other condition that could compromise treatment or increase the risk of a procedure-related injury;
  11. Is using any systemic or topical medications that in the opinion of the investigator may affect a study outcome variable;
  12. Has known sensitivity to the diagnostic pharmaceuticals to be used in the study;
  13. Has a history of sensitivity to rapidly blinking lights or photosensitive epilepsy;
  14. Is pregnant, lactating or planning a pregnancy (by verbal communication) at the time of enrolment;
  15. Is aphakic;
  16. Is a member of CORE directly involved in the study;
  17. Has taken part in a clinical research study within the last 30 days. * For the purposes of this study, active ocular disease is defined as infection or inflammation which requires therapeutic treatment. Mild (i.e. not considered clinically relevant) lid abnormalities (blepharitis, meibomian gland dysfunction, papillae), corneal and conjunctival staining and dry eye are not considered active ocular disease. Neovascularization and corneal scars are the result of previous hypoxia, infection or inflammation and are therefore not active.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04159935


Contacts
Layout table for location contacts
Contact: Jill Woods, MCOptom 519-888-4567 ext 36743 jwoods@uwaterloo.ca

Locations
Layout table for location information
Canada, Ontario
Centre for Ocular Research & Education Recruiting
Waterloo, Ontario, Canada, N2L 3G1
Contact: Jill Woods, MCOptom    519-888-4567 ext 36743    jwoods@uwaterloo.ca   
Principal Investigator: Lyndon Jones, PhD, FCOptom         
Sponsors and Collaborators
University of Waterloo
Alcon Research
Investigators
Layout table for investigator information
Principal Investigator: Lyndon Jones, PhD, FCOptom Centre for Ocular Research & Education
Layout table for additonal information
Responsible Party: University of Waterloo
ClinicalTrials.gov Identifier: NCT04159935    
Other Study ID Numbers: 41401
First Posted: November 12, 2019    Key Record Dates
Last Update Posted: November 19, 2019
Last Verified: November 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Product Manufactured in and Exported from the U.S.: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Keratoconjunctivitis Sicca
Dry Eye Syndromes
Eye Diseases
Keratoconjunctivitis
Conjunctivitis
Conjunctival Diseases
Keratitis
Corneal Diseases
Lacrimal Apparatus Diseases